|   From the Trenches

Will Clinical Trials Make a House Call?

I love to travel. While still in training in internal medicine, I earned extra money to fund trips abroad by covering for community-based general practitioners (GPs). This usually involved staying in the GP’s house for the weekend, holding the cell phone and carrying a medical bag in what I call ‘the boot’. I am a country girl at heart and driving around the Irish countryside between seeing a couple of patients at the practice was a nice escape from the city.

By Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   In the News

Atlas Venture Raises $400M Fund to Seed Another New Set of Biotechs

Another venture capital firm that backs biotechs has raised a multimillion-dollar fund—money the firm, Cambridge, MA-based Atlas Venture, says it will use to continue creating and funding companies that are working to create new medicines.

Read more.


  |   Press Release

Atlas Venture Announces $400 Million Fund XII and Expansion of Partnership

Atlas Venture, a leading early stage venture capital firm investing in groundbreaking biotech innovation, today announced the closing of its twelfth fund, raising $400 million in a highly oversubscribed fundraise. With the closing of Fund XII, Michael Gladstone was promoted to partner. Atlas Venture will continue to advance its mission of doing well by doing good, building biotech companies to deliver high-impact therapies to patients.

Read more.


  |   From the Trenches

Controlling Your Destiny: Why Investment in Manufacturing Capabilities Makes Sense

Manufacturing of medicines based on biology is complex. Viral vector manufacturing to produce gene therapy constructs, vaccines and oncolytic viruses is especially intricate. Most early stage companies use contract manufacturing organizations until real clinical proof of principle is achieved as a logical decision inflection point for investing in in-house manufacturing, versus continuing to use a CMO for pivotal studies and launch.

By Philip Astley-Sparke, CEO of Replimune, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   In the News

Q32 debuts with $46M to ‘rebalance’ innate and adaptive immunity

Many autoimmune diseases are treated with immunosuppressive drugs to rein in an immune system that has turned on the body’s own tissues. Problem is, that approach doesn’t just tamp down the immune response in affected tissues—it affects immune cells throughout the body. Enter Q32 Bio, which is working on a new generation of treatments for autoimmune and inflammatory diseases.

Read more.